The Mag


With the vaccine business made lucrative by the COVID-19 pandemic, and more and more ATMPs in clinical testing, providers such as CDMOs are also expanding their capacity to produce vectors and alternative tools for delivery. Add to this: After the first eleven approvals of gene therapies for rare diseases and cell therapies for blood cancer, there are a large number of candidates being tested in clinical trials. Digitalisation is becoming increasingly important for both CDMOs and CROs.

In this issue:

  • Technology expansion
  • Interview: Christian Schetter, CSO, Rentschler Biopharma SE
  • CRO of the future
  • Innovation in drug development
  • Bringing virotherapy forward
  • Interview: Dimitrios Wagner, Charité
  • CB21 R&D: CDMO for endocannabinoids
  • Vector BioPharma: the future of gene delivery